31 March 2023

Both medical and technological developments have led to the increased provision of cancer medicines on the market, making it possible for cancer patients to live longer with a better quality of life. However, currently, the only way to bring innovative therapies to patients is via a commercial route, with extremely high prices.

With this webinar, MEPs Against Cancer invited panellists representing the European Commission, the European Medicines Agency, researchers, and patients in a discussion on the main bottlenecks that hinder academic development of medicines and how to overcome them.

As the longest-standing group of MEPs dedicated to addressing the entire cancer continuum – from prevention and treatment to survivorship – the MEPs Against Cancer group brings together policymakers from across the political spectrum and EU member states to promote ambitious EU action against cancer. The group is supported by the Association of European Cancer Leagues (ECL), which unites 33 national and regional cancer leagues across Europe.